Risks of Proton Pump Inhibitors in Patients with Cirrhosis: Please Peruse the Indications

En Xian Sarah Low, Yen Po Wang, Ching Liang Lu*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

The use of proton pump inhibitor (PPI) in cirrhotic patients can be associated with increased risks of long-term mortality, decompensation, hepatic encephalopathy, spontaneous bacterial peritonitis, and infection, but not with short-term mortality. Ensure clear indications at lowest effective dose of is mandatory for the use of PPI among cirrhotic patients.

Original languageEnglish
JournalDigestive Diseases and Sciences
DOIs
StateAccepted/In press - 2023

Keywords

  • Cirrhosis
  • Hepatic decompensation
  • Hepatocellular carcinoma
  • Proton pump inhibitors
  • Spontaneous bacterial peritonitis

Fingerprint

Dive into the research topics of 'Risks of Proton Pump Inhibitors in Patients with Cirrhosis: Please Peruse the Indications'. Together they form a unique fingerprint.

Cite this